MedTrace Logo

Early Intervention in COVID-19: Favipiravir Verses Standard Care

NCT04373733 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 502

Last updated 2021-11-18

No results posted yet for this study

Summary

Currently we do not know how best to treat patients infected with COVID-19. This study is looking at whether randomising participants to either favipiravir or to usual care, can help patients with suspected or proven COVID-19 infection.

Conditions

  • Coronavirus Infection

Interventions

DRUG

Favipiravir

Anti-viral

OTHER

Standard of care management

Standard of care management for COVID-19

Sponsors & Collaborators

  • NEAT ID Foundation

    collaborator OTHER

  • FUJIFILM Toyama Chemical Co., Ltd.

    collaborator INDUSTRY

  • Imperial College London

    collaborator OTHER

  • Chelsea and Westminster NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Pallav Shah · Chelsea and Westminster NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2021-06-25
Completion
2021-06-25

Countries

  • Brazil
  • Mexico
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04373733 on ClinicalTrials.gov